Lack of an Association between the SDF-1 rs1801157 Polymorphism and Coronary Heart Disease: A Meta-Analysis

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Nan Wu1, Xiaowen Zhang2, Pengyu Jia3

  • 1Department of Cardiology, The First Affiliated Hospital of China Medical University, Liaoning, China.

Scientific Reports
|July 3, 2015
PubMed

Insights

The stromal cell-derived factor-1 (SDF-1) gene polymorphism rs1801157 is not linked to coronary heart disease (CHD) risk. However, this SNP may decrease susceptibility to myocardial infarction (MI).

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology
  • Molecular Biology

Background:

  • Single-nucleotide polymorphisms (SNPs) in the stromal cell-derived factor (SDF)-1 gene, specifically rs1801157, have been implicated in coronary heart disease (CHD) susceptibility.
  • Previous research on the association between rs1801157 and CHD risk has yielded inconsistent findings.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis evaluating the association between the SDF-1 gene polymorphism rs1801157 and the risk of coronary heart disease (CHD).
  • To clarify the conflicting results reported in the existing literature regarding this genetic association.

Main Methods:

  • A systematic literature search was conducted across major databases including PubMed, Web of Science, Cochrane Library, CNKI, and Wan Fang.
  • Seven eligible studies comprising 4656 cases and 2654 controls were included in the meta-analysis.
  • Statistical methods were employed to assess heterogeneity and potential publication bias.

Main Results:

  • The meta-analysis found no statistically significant association between the rs1801157 polymorphism and overall CHD risk across all genetic models.
  • Subgroup analyses revealed that rs1801157 was associated with a decreased susceptibility to myocardial infarction (MI).
  • No association was observed between rs1801157 and CHD susceptibility in either Caucasian or Asian populations.

Conclusions:

  • The rs1801157 polymorphism in the SDF-1 gene is not associated with the overall risk of developing coronary heart disease (CHD).
  • A potential protective association exists between the rs1801157 polymorphism and the risk of myocardial infarction (MI).
  • Further large-scale, well-designed case-control studies are warranted to validate these findings and confirm the role of rs1801157 in cardiovascular disease.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.7K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
861
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
996
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119